Novo Nordisk A/S (NYSE:NVO) Raised to "Hold" at Zacks Research

Key Points

• Zacks Research upgraded Novo Nordisk to “Hold” from “Strong Sell,” aligning with MarketBeat’s consensus “Hold” rating from four Buy and 16 Hold recommendations. The consensus price target is $64.94.
• Novo Nordisk shares opened at $46.52, down 1.4%, with a market capitalization of about $207.7 billion. The stock trades at a P/E ratio of 11.37 and has ranged between $35.12 and $64.16 over the past year.
• The company reported quarterly EPS of $0.94 on $11.98 billion in revenue, while investors continue to weigh growth opportunities from oral Wegovy and diabetes treatments against pressure from Eli Lilly, pricing concerns and pipeline setbacks.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) was upgraded by research analysts at Zacks Research from a "strong sell" rating to a "hold" rating in a report released on Tuesday,Zacks.com reports.

Several other analysts also recently commented on the company. Weiss Ratings raised Novo Nordisk A/S from a "sell (d+)" rating to a "hold (c-)" rating in a research note on Wednesday, August 5th. Wall Street Zen cut shares of Novo Nordisk A/S from a "buy" rating to a "hold" rating in a research report on Saturday, June 20th. Nordea Equity Research raised Novo Nordisk A/S from a "hold" rating to a "buy" rating in a research report on Friday, June 19th. Citigroup restated a "neutral" rating on shares of Novo Nordisk A/S in a research note on Monday, July 20th. Finally, HSBC reiterated a "hold" rating on shares of Novo Nordisk A/S in a research note on Monday, July 6th. Four analysts have rated the stock with a Buy rating and sixteen have assigned a Hold rating to the company's stock. Based on data from MarketBeat, Novo Nordisk A/S currently has a consensus rating of "Hold" and a consensus target price of $64.94.

Novo Nordisk A/S Stock Down 1.4%

NVO stock opened at $46.52 on Tuesday. The firm has a 50-day simple moving average of $47.24 and a 200-day simple moving average of $44.61. The company has a quick ratio of 0.56, a current ratio of 0.79 and a debt-to-equity ratio of 0.59. The stock has a market capitalization of $207.71 billion, a P/E ratio of 11.37, a P/E/G ratio of 4.30 and a beta of 0.76. Novo Nordisk A/S has a 52 week low of $35.12 and a 52 week high of $64.16.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last announced its quarterly earnings results on Tuesday, June 30th. The company reported $0.94 EPS for the quarter. Novo Nordisk A/S had a return on equity of 61.20% and a net margin of 35.36%.The business had revenue of $11.98 billion for the quarter. Equities analysts forecast that Novo Nordisk A/S will post 3.39 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Novo Nordisk A/S

Hedge funds have recently made changes to their positions in the business. Godfrey Financial Associates Inc. bought a new stake in shares of Novo Nordisk A/S in the 4th quarter worth about $25,000. WealthCollab LLC increased its position in Novo Nordisk A/S by 93.5% during the fourth quarter. WealthCollab LLC now owns 538 shares of the company's stock worth $27,000 after buying an additional 260 shares during the last quarter. Jackson Grant Investment Advisers Inc. bought a new position in Novo Nordisk A/S in the 4th quarter valued at about $29,000. Transamerica Financial Advisors LLC raised its position in shares of Novo Nordisk A/S by 201.5% in the 4th quarter. Transamerica Financial Advisors LLC now owns 603 shares of the company's stock valued at $31,000 after buying an additional 403 shares in the last quarter. Finally, Quaker Wealth Management LLC lifted its holdings in shares of Novo Nordisk A/S by 186.0% during the 4th quarter. Quaker Wealth Management LLC now owns 615 shares of the company's stock worth $31,000 after acquiring an additional 400 shares during the period. Institutional investors and hedge funds own 11.54% of the company's stock.

Key Headlines Impacting Novo Nordisk A/S

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: CEO Mike Doustdar said the obesity-drug market is unlikely to be “winner-take-all,” arguing that patients will seek differentiated treatments, including pills. This supports Novo’s ability to compete beyond its current injectable products. Reuters article
• Positive Sentiment: Oral Wegovy prescriptions reportedly reached a record, while management sees a long runway for GLP-1 adoption as obesity remains widespread and treatment could eventually reduce healthcare costs. Fox Business article
• Positive Sentiment: Novo’s once-weekly basal insulin Awiqli is now available in the United States, adding a commercial opportunity in diabetes care beyond the obesity franchise. Awiqli availability article
• Neutral Sentiment: Erste Group raised its FY2026 EPS estimate to $3.27 from $3.20, although that remains below the broader consensus estimate of $3.39. Erste Group estimate article
• Negative Sentiment: Berenberg downgraded NVO from “buy” to “hold,” saying much of the anticipated Wegovy-pill upside is already reflected in the valuation and that the stock’s multiple may revert toward the European pharmaceutical average. Berenberg downgrade article
• Negative Sentiment: Management acknowledged that Eli Lilly is gaining market share. Investors remain concerned about flat Wegovy sales, pricing pressure, pipeline setbacks and Lilly’s competitive position in oral obesity treatments. BeInCrypto article
• Negative Sentiment: Novo is defending a lawsuit against Lilly over weight-loss-drug advertising. Although the company says competition must be fair, the litigation adds uncertainty and could distract from the commercial battle. CNBC article

Novo Nordisk A/S Company Profile

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source